BR0014294A - Quinazolinones - Google Patents

Quinazolinones

Info

Publication number
BR0014294A
BR0014294A BR0014294-8A BR0014294A BR0014294A BR 0014294 A BR0014294 A BR 0014294A BR 0014294 A BR0014294 A BR 0014294A BR 0014294 A BR0014294 A BR 0014294A
Authority
BR
Brazil
Prior art keywords
quinazolinones
ibix
solvates
salts
formula
Prior art date
Application number
BR0014294-8A
Other languages
Portuguese (pt)
Inventor
Werner Mederski
Ralf Devant
Gerhard Barnickel
Sabine Bernotat-Danielowski
Guido Melzer
Daljit Dhanoa
Bao-Ping Zhao
James Rinker
Mark Player
Richard Soll
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0014294A publication Critical patent/BR0014294A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"QUINAZOLINONAS". Quinazolinonas de fórmula ( I ) em que R, R^ 1^, R^ 2^, R^ 3^, R^ 4^, Y, Z, n e m possuem os significados indicados na reivindicação 1 da patente, e seus sais ou solvatos como antagonistas de glicoproteína IbIx."QUINAZOLINONES". Quinazolinones of formula (I) in which R, R ^ 1 ^, R ^ 2 ^, R ^ 3 ^, R ^ 4 ^, Y, Z, do not even have the meanings indicated in patent claim 1, and their salts or solvates as IbIx glycoprotein antagonists.

BR0014294-8A 1999-09-28 2000-09-13 Quinazolinones BR0014294A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40795899A 1999-09-28 1999-09-28
PCT/EP2000/008940 WO2001023365A1 (en) 1999-09-28 2000-09-13 Quinazolinones

Publications (1)

Publication Number Publication Date
BR0014294A true BR0014294A (en) 2002-05-21

Family

ID=23614261

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014294-8A BR0014294A (en) 1999-09-28 2000-09-13 Quinazolinones

Country Status (8)

Country Link
EP (1) EP1216235A1 (en)
KR (1) KR20020047186A (en)
AR (1) AR025797A1 (en)
AU (1) AU7654800A (en)
BR (1) BR0014294A (en)
CA (1) CA2385921A1 (en)
NO (1) NO20021502L (en)
WO (1) WO2001023365A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
TW200401770A (en) * 2002-06-18 2004-02-01 Sankyo Co Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof
US20040152696A1 (en) * 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
JP2006512315A (en) * 2002-11-04 2006-04-13 エヌピーエス ファーマスーティカルズ インコーポレイテッド Quinazolinone compounds as calcilytics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670416A1 (en) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Process for the preparation of amino-substituted quinazolinone derivatives
JPS6136273A (en) * 1984-07-26 1986-02-20 Mitsubishi Yuka Yakuhin Kk 2-phenylalkyl-4(3h)-quinazolinone derivative
EP0749974B1 (en) * 1994-03-08 2001-06-27 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
US5783577A (en) * 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof

Also Published As

Publication number Publication date
WO2001023365A1 (en) 2001-04-05
AR025797A1 (en) 2002-12-11
EP1216235A1 (en) 2002-06-26
CA2385921A1 (en) 2001-04-05
AU7654800A (en) 2001-04-30
NO20021502D0 (en) 2002-03-26
KR20020047186A (en) 2002-06-21
NO20021502L (en) 2002-03-26

Similar Documents

Publication Publication Date Title
BR0114020A (en) 4-amino-quinazolines
BR0007527A (en) Phenylphenanthridines with IV-dependent inhibitory activity
BR9815518A (en) Antibacterial oxazolidinone agents having thiocarbonyl functionality
BR0111222A (en) Phosphonated glycopeptide derivatives
BR0014078A (en) Xa factor inhibitors
PT1140944E (en) EPOTILONE DERIVATIVES AND THEIR USE AS ANTITUMATIC AGENTS
TR199801255T2 (en) Vitronectin receptor antagonists.
BR9916111A (en) Phenylglycine derivatives
BRPI0007487B8 (en) diphenyl-ureas substituted with w-carboxy-aryls as raf kinase inhibitors
TR200200795T2 (en) Piperazine derivatives as 5-HT1B antagonists
BR0007595A (en) 4- (heterocyclisulfonamido) -5-methoxy-6- (2-methoxyphenoxide) -2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists
ATE234812T1 (en) INTEGRIN ANTAGONISTS
ES2184077T3 (en) NEW FENANTRIDINS REPLACED IN POSITION 6.
PT998460E (en) NEW TETRAZOLE DERIVATIVES
BR0014311A (en) Quinazolinones
ATE416157T1 (en) INHIBITORS OF INTEGRIN ALPHA-V-BETA-6
BR0209440A (en) Sulfonamides
BR9909486A (en) Calcilic compounds
BR9803704A (en) Quinazoline-4-one as ampa antagonists.
TR199701645A2 (en) Vitronectin receptor antagonists, their manufacture and use
BR9915611A (en) Benzo [de] substituted isoquinoline-1,3-diones
BR9607335A (en) 1-aryl-2-acrylamino-ethane compounds and their use as neurokinin especially neurokinin antogonists 1
BR9910032A (en) Thienopyrimidines
BR9916324A (en) 4,5-pyrazinoxindoles as protein kinase inhibitors
BR9915648A (en) Benzo [de] substituted isoquinoline-1,3-diones

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]